• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.03% Nasdaq Up1.29%

    Incyte Corporation (INCY)

    -NasdaqGS
    98.28 Up 1.12(1.15%) May 1, 4:00PM EDT
    |After Hours : 98.28 0.00 (0.00%) May 1, 4:11PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Incyte Corporation
    1801 Augustine Cut-Off
    Wilmington, DE 19803
    United States - Map
    Phone: 302-498-6700
    Website: http://www.incyte.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:588

    Business Summary 

    Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

    Key Statistics


    Company Websites 
    Home Page
    Products & Services
    Subsidiaries
    Search Yahoo! for:
    More on Incyte Corporation

    Corporate Governance 
    Incyte Corporation’s ISS Governance QuickScore as of Apr 1, 2015 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Herve Hoppenot , 54
    Chief Exec. Officer, Pres, Director and Member of Non-Management Stock Option Committee
    4.55MN/A
    Mr. David W. Gryska MBA, 60
    Chief Financial Officer and Exec. VP
    208.00KN/A
    Dr. Reid M. Huber Ph.D., 43
    Chief Scientific Officer and Exec. VP
    642.00K7.85M
    Dr. Richard S. Levy M.D., 57
    Chief Drug Devel. Officer and Exec. VP
    701.00K17.08M
    Mr. James M. Daly MBA, 53
    Chief Commercial Officer and Exec. VP
    902.00K12.30M
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders